Perceptions and Preferences of Indian Clinicians Towards Metoprolol–Am lodipine Fixed-Dose Combination Therapy in Hypertension Management: A Cross-Sectional Survey-Based Study

Authors

  • Roopa Ravi Babu Cardiologist, Heart Care Centre, Bangalore, Karnataka, India
  • Sreedhara CG Consultant Nephrologist, Trinity Hospital and Heart Foundation, Basavanagudi, Bangalore, Karnataka, India
  • Niranjan K Consultant Cardiologist, RL Jalappa Narayana Heart Centre, Kolar, Karnataka, India
  • Aashish A Consultant Cardiologist, Dr. Aashish Heart and Diabetes Clinic, Chennai, Tamil Nadu, India
  • Sel Varathinasamy CS Consultant Neurologist, Pills Hospital, Coimbatore, Tamil Nadu, India
  • Anurag Srivastav Consultant Cardiologist, Brahma Nagar Colony, Jhansi, Uttar Pradesh, India
  • Zaheer A Virani Consultant Nephrologist, Masina Hospital, Mumbai, Maharashtra, India
  • Ranabrata Sen Consultant Cardiologist, Medisage Cardiology, Cooch Behar, West Bengal, India
  • Ashish Singhal Consultant Cardiologist, Signature Heart & Multi Speciality Hospital, Delhi, India
  • Manoop Mittal Interventional Cardiologist, Noble Heart and Super Speciality Hospital, Haryana, India
  • Manjula S Department of Medical Services, Micro Labs Ltd, Bangalore, Karnataka, India
  • Krishna Kumar M Department of Medical Services, Micro Labs Ltd, Bangalore, Karnataka, India

DOI:

https://doi.org/10.48165/ajm.2026.9.01.25

Keywords:

Hypertension, Fixed-Dose Combination, Metoprolol, Amlodipine, Clinician Survey, Antihypertensive Therapy.

Abstract

Background:Hypertension remains a leading contributor to cardiovascular morbidity and mortality in India. Combination therapy using fixed-dose formulations like Metoprolol (a β-blocker) and Amlodipine (a calcium channel blocker) has gained attention for improved compliance and synergistic efficacy. However, clinician perspectives on such combinations remain underreported in Indian settings. Objective:To assess the perceptions, prescribing preferences, and clinical rationale of Indian medical professionals regarding the use of Metoprolol–Amlodipine fixed-dose combination (FDC) therapy in the management of hypertension.Methods:A descriptive, cross-sectional survey was conducted among 112 practicing clinicians using a structured questionnaire. The tool captured demographic details, prescribing patterns, therapeutic rationale, patient age-related choices, and perceived benefits or limitations of the Metoprolol–Amlodipine FDC.Results:The majority of respondents (78.6%) preferred the Metoprolol–Amlodipine combination over other antihypertensive FDCs, particularly in younger patients and those with coexisting anxiety or high sympathetic tone. Perceived advantages included effective BP control (86%), improved adherence (72%), and symptom relief. Logistic regression revealed significant associations between clinician age group, years of experience, and preference for the combination (p < 0.05).Conclusion:Indian clinicians show a strong preference for Metoprolol–Amlodipine FDC therapy, attributing it to enhanced therapeutic efficacy, tolerability, and patient compliance. These findings support the growing clinical utility of β-blocker–CCB combinations in routine hypertension management and underscore the need for updated guidelines reflecting real-world practices.

References

Piepoli, M. F., Hoes, A. W., Agewall, S., et al. (2021). 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337. https://doi.org/10.1093/eurheartj/ehab484

Castellano, J. M., Sanz, G., Peñalvo, J. L., et al. (2022). A polypill strategy to improve adherence: Results from the FOCUS study. Journal of the American College of Cardiology, 69(6), 628–639. https://doi.org/10.1016/j.jacc.2021.11.055

Petrella, R. J., Merikle, E., & Jones, J. (2021). Treatment inertia in patients with high cardiovascular risk: A real-world analysis. Cardiovascular Diabetology, 20(1), 46. https://doi.org/10.1186/s12933-021-01203-0

Franz, R. M., Braun, S., & Metzner, A. (2022). Clinical use of beta-blockers in elderly patients with coronary artery disease. Drugs & Aging, 39(2), 91–100. https://doi.org/10.1007/s40266-021-00908-7

Kumar, A., Sharma, M., & Jindal, N. (2023). Comparative efficacy of nebivolol vs other beta-blockers in CAD: A clinical review. American Journal of Cardiovascular Drugs, 23(1), 11–21. https://doi.org/10.1007/s40256-022-00529-8

Gupta, M., Singh, N., & Gupta, R. (2022). Role of combination therapy in hypertension: Amlodipine plus beta-blockers. Journal of the Association of Physicians of India, 70(5), 42–46. https://doi.org/10.59556/japi.70.0072

Jamerson, K., Weber, M. A., Bakris, G. L., et al. (2021). Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine, 359(23), 2417–2428. https://doi.org/10.1056/NEJMoa0806182

Zhang, W., Liu, Y., Sun, H., et al. (2023). Telmisartan attenuates endothelial dysfunction and oxidative stress via PPAR-γ activation in high-fat diet rats. Scientific Reports, 13(1), 10341. https://doi.org/10.1038/s41598-023-37549-y

Mobini, M., Aghaei, N., Gholami, M., et al. (2023). Medication adherence and its related factors in patients with cardiovascular disease: A cross-sectional study. BMC Cardiovascular Disorders, 23(1), 145. https://doi.org/10.1186/s12872-023-03191-4

Komiyama, Y., & Tanabe, K. (2022). The COMPELL study: Cilnidipine vs amlodipine for pedal edema in hypertension. Clinical and Experimental Hypertension, 44(6), 578–584. https://doi.org/10.1080/10641963.2022.2050232

PREVENT Collaborative Group. (2021). Effects of cilnidipine vs amlodipine on pedal edema in hypertensive patients. Journal of Clinical Hypertension, 23(1), 17–24. https://doi.org/10.1111/jch.14097

Mahajan, H., Kazi, Y., & Sharma, B. (2023). Cardiovascular risk factors among urban slum dwellers: A cross-sectional study. International Journal of Health Policy and Management, 12(1), 1053–1059. https://doi.org/10.34172/ijhpm.2023.106

Yusuf, S., Hawken, S., Ounpuu, S., et al. (2022). INTERHEART study: Modifiable risk factors for myocardial infarction across 52 countries. The Lancet, 364(9438), 937–952. https://doi.org/10.1016/S0140-6736(04)17018-9

Arnett, D. K., Blumenthal, R. S., Albert, M. A., et al. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary. Journal of the American College of Cardiology, 74(10), 1376–1414. https://doi.org/10.1016/j.jacc.2019.03.009

Bansilal, S., Castellano, J. M., & Fuster, V. (2015). Global burden of cardiovascular disease: Focus on secondary prevention of cardiovascular disease. International Journal of Cardiology, 201(Suppl. 1), S1–S7. https://doi.org/10.1016/S0167-5273(15)31026-3

Sahoo, S., Sethy, G., Sahoo, S. K., et al. (2023). Efficacy and safety of fixed-dose combination of metoprolol and amlodipine in Indian patients with hypertension and CAD: A real-world evidence study. Indian Heart Journal, 75(4), 327–334. https://doi.org/10.1016/j.ihj.2023.07.002

Mahajan, K., Negi, P. C., Merwaha, R., et al. (2022). Burden of coronary artery disease and its risk factors in Himachal Pradesh: Results from a population-based study. Indian Heart Journal, 74(5), 431–438. https://doi.org/10.1016/j.ihj.2022.08.004

Zhao, D., Liu, J., Wang, M., Zhang, X., & Zhou, M. (2019). Epidemiology of cardiovascular disease in China: Current features and implications. Nature Reviews Cardiology, 16(4), 203–212. https://doi.org/10.1038/s41569-018-0119-4

Krittanawong, C., Virk, H. U. H., Kumar, A., et al. (2022). Trends in adherence to secondary prevention guidelines for coronary artery disease among US adults: NHANES 2001–2016. European Journal of Preventive Cardiology, 29(9), 1389–1398. https://doi.org/10.1093/eurjpc/zwab175

Gupta, R., Joshi, P., Mohan, V., Reddy, K. S., & Yusuf, S. (2008). Epidemiology and causation of coronary heart disease and stroke in India. Heart, 94(1), 16–26. https://doi.org/10.1136/hrt.2007.132951

Downloads

Published

2026-03-28

Issue

Vol. 9 No. 1 (2026): Academia Journal of Medicine(Jan-Jun)

Section

Research Article

How to Cite

Perceptions and Preferences of Indian Clinicians Towards Metoprolol–Am lodipine Fixed-Dose Combination Therapy in Hypertension Management: A Cross-Sectional Survey-Based Study. (2026). Academia Journal of Medicine, 9(1), 113-123. https://doi.org/10.48165/ajm.2026.9.01.25